Therapeutic Targets Database
BIDD Pharmainformatics Databases
 
   
   

 

TTD Drug ID: DAP000133

Drug Information
NameRepaglinide
SynonymsSAM001246546; NCGC00016978-01; Novo Nordisk brand of repaglinide; Glaxo Wellcome brand of replaginide; D00594; 135062-02-1; AC-726; C27H36N2O4; 2-ethoxy-N-(alpha-(2-methyl-1-propyl)-2-piperidinobenzyl)-4-carbamoylmethylbenzoic acid; MLS001076684; MolPort-003-850-140; Repaglinida [INN-Spanish]; AC1L24D5; (+)-2-Ethoxy-alpha-(((S)-alpha-isobutyl-o-piperidinobenzyl)carbamoyl)-p-toluic acid; CAS-135062-02-1; AG-EE 388; (S)-(+)-2-Ethoxy-4-[N-[1-(2-piperidinophenyl)-3-methyl-1-butyl]aminocarbonylmethyl]benzoic acid; Prestwick0_001046; GlucoNorm; AGEE-623ZW; Actulin; 2-ethoxy-4-[2-[[(1S)-3-methyl-1-(2-piperidin-1-ylphenyl)butyl]amino]-2-oxoethyl]benzoic acid; Repaglinide; SMP-508; AG-EE-388; (S)-2-Ethoxy-4-(2-((methyl-1-(2-(1-piperidinyl)phenyl)butyl)amino)-2-oxoethyl)-benzoic acid; MLS000759407; CID65981; AC1Q5TZW; Prestwick3_001046; SMR000466305; Repaglinidum; BPBio1_001070; Prandin, GlucoNorm, NovoNorm, Repaglinide; AG-EE-623 ZW; NCGC00016978-02; C07670; Repaglinide [USAN]; STK629501; LS-38509; Prestwick1_001046; NovoNorm; UNII-668Z8C33LU; repa-glinide; Prestwick2_001046; CHEBI:348669; DB00912; AG-EE 623 ZW; AG-EE 388 ZW; 2-ethoxy-4-(2-{[(1S)-3-methyl-1-(2-piperidin-1-ylphenyl)butyl]amino}-2-oxoethyl)benzoic acid; HMS2051N08; Bio-0087; Novo Nordisk brand 2 of repaglinide; BSPBio_000972; HMS1571A14; repaglinide, (+-)-isomer; 2-ethoxy-4-(2-((3-methyl-1-(2-(1-piperidinyl)phenyl)butyl)amino)-2-oxoethyl)benzoic acid; 2-ethoxy-4-[2-({(1S)-3-methyl-1-[2-(piperidin-1-yl)phenyl]butyl}amino)-2-oxoethyl]benzoic acid; HMS2094C07; Prandin; C072379; NN-623; Repaglinidum [INN-Latin]; Repaglinide (JAN/USP/INN); BIDD:GT0338; S1426_Selleck; CPD000466305; AB00514019; CHEMBL1272; R9028_SIGMA; SPBio_002906; (S)-2-ethoxy-4-(2-((3-methyl-1-(2-(1-piperidinyl)-phenyl)butyl)amino)-2-oxoethyl)-benzoic acid; 111GE012; BRD-K82846253-001-03-0; Prandin (TN); Benzoic acid, 2-ethoxy-4-(2-((3-methyl-1-(2-(1-piperidinyl)phenyl)butyl)amino)-2-oxoethyl)-, (S)-; Repaglinida
Trade NamePrandin; GlucoNorm; NovoNorm
CompanyNovo Nordisk
IndicationDiabetes mellitus
[ICD9: 250   ICD10: E08-E13]
Approved    [1]
Structure

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
InChI1S/C27H36N2O4/c1-4-33-25-17-20(12-13-22(25)27(31)32)18-26(30)28-2
3(16-19(2)3)21-10-6-7-11-24(21)29-14-8-5-9-15-29/h6-7,10-13,17,19
,23H,4-5,8-9,14-16,18H2,1-3H3,(H,28,30)(H,31,32)/t23-/m0/s1
InChIKeyFAEKWTJYAYMJKF-QHCPKHFHSA-N
Canonical SMILESCCOC1=C(C=CC(=C1)CC(=O)NC(CC(C)C)C2=CC=CC=C2N3CCCCC3)C(=O)O    
Isomeric SMILESCCOC1=C(C=CC(=C1)CC(=O)N[C@@H](CC(C)C)C2=CC=CC=C2N3CCCCC3)C(=O)O
Therapeutic ClassHypoglycemic Agents
CAS NumberCAS 135062-02-1
FormulaC27H36N2O4
PubChem Compound IDCID 65981.
PubChem Substance IDSID 9872.
SuperDrug ATC IDA10BX02
SuperDrug CAS ID135062021;
TargetSUR1-type K(ATP) channelBlocker[2][3][4]
SUR2-type K(ATP) channelBlocker[2][3][4]
Ref 1FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 077571 To Reference
Ref 2Metformin/Repaglinide (PrandiMet) for type 2 diabetes. Med Lett Drugs Ther. 2009 Jun 1;51(1313):41-3. To Reference
Ref 3Pharmacological modulation of K(ATP) channels. Biochem Soc Trans. 2002 Apr;30(2):333-9. To Reference
Ref 4Clinical pharmacokinetics and pharmacodynamics of repaglinide. Clin Pharmacokinet. 2002;41(7):471-83. To Reference



 

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.


Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore


All rights reserved.

   
 
 
Computer-aided Drug Design
about BIDD |  databases |  software |  teaching |  research |  links

 

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543